Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Core Insights - Femasys, Inc. has secured strategic distribution partnerships for its CE-marked products, FemaSeed® and FemVue®, in Spain, marking a significant step in its global expansion [1][2] - The distribution partners, Comercial Medico Quirurigca, SA (CMQ) and Durgalab, are committed to purchasing a minimum of $1.3 million of FemaSeed over the next year, indicating strong confidence in expanding access to these products [2] Company Overview - Femasys is a biomedical company focused on addressing unmet needs of women with a portfolio of innovative therapeutic and diagnostic solutions, including FemaSeed® for infertility treatment and FemBloc® for permanent birth control [5] - FemaSeed® is designed to deliver sperm directly where conception occurs and has received regulatory approval in Canada and Europe, while FemBloc® is in late-stage clinical development as a non-surgical birth control method [5] Spanish Infertility Market - Spain has the highest number of in vitro fertilization (IVF) clinics in Europe, with 244 facilities, and ranks second in intrauterine insemination (IUI) cycles using husband sperm, as well as leading in IUI cycles using donor sperm [3]